FDA Determines Regulatory Review Period for KEYTRUDA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its decision regarding the regulatory review period for the patent extension of KEYTRUDA, a human biological product, following a submission to the U.S. Patent and Trademark Office (USPTO).